After a PhD degree in chemistry from the Technical University of Vienna, Austria, and a postdoctoral fellowship from the California Institute of Technology, USA, Helmut held research and managerial positions in national and international pharmaceutical companies including Kwizda Pharma, Sandoz and Boehringer-Ingelheim. He joined Axentis Pharma as CEO in 2009.
Ivan has a longstanding experience in Business Development. He has been working for 30 years (until February 2009) at Ciba-Geigy and Novartis, the first seven years as laboratory head in antibiotics chemistry research, afterwards for 23 years in the Business Development & Licensing Department, where he was responsible for in and/or out-licensing of drugs in different therapeutic areas, including CNS, dermatology, inflammation, oncology, respiratory, as well as for drug delivery projects. He has negotiated and concluded numerous option and license agreements with pharmaceutical and medical device companies, more recently with companies such as Abbott Vascular, Eisai, Speedel.
Ivan is a founding member of Swiss Pharma Licensing Group and was the President of the association from 2004-2008. He is currently chairman of European Pharma Licensing Council.
Peter has a PhD in organic chemistry from the University of Basel and did his postdoc in Biochemistry at Purdue University, USA. He joined Ciba Geigy in 1975 and worked for the company in various leading positions in pharmaceutical development, drug delivery and in chemicals and personal care products until his retirement in 2001. Peter then founded MANDAPRO (= "Mandates and Projects"), Basel, where he is Chairman and CEO. In this function, Peter signed responsible for the re-development and registration of the liposomal product MEPACT (launched February 2010 by Takeda).